Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
Executive Summary
Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.
You may also be interested in...
Vertex: Preparing to Go Commercial
With perhaps little over a year to go before it files its NDA for hepatitis C hopeful telaprevir, Vertex is gearing up for its transition to a commercially focused company. New CEO Matt Emmens talks to IN VIVO about the financial and cultural challenges of building a commercial organization to match Vertex's highly productive R&D.
Vertex: Preparing to Go Commercial
With perhaps little over a year to go before it files its NDA for hepatitis C hopeful telaprevir, Vertex is gearing up for its transition to a commercially focused company. New CEO Matt Emmens talks to IN VIVO about the financial and cultural challenges of building a commercial organization to match Vertex's highly productive R&D.
In HCV, Protease Race Heats Up with Combo Therapy Looming
Two Phase III hepatitis C protease inhibitors from Vertex and Schering are set to reshape treatment for a difficult disease and potentially capture a significant chunk of a large and growing market. But other new therapies and combination regimens aren't far behind.